NCT03997968 2024-12-24
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Cyteir Therapeutics, Inc.
Phase 1/2 Completed
Cyteir Therapeutics, Inc.
Jazz Pharmaceuticals
Eli Lilly and Company
OHSU Knight Cancer Institute
National Cancer Institute (NCI)